Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9MB4

Metal Beta Lactamase NDM-1 in Complex with Dual MBL/SBL Inhibitor 14

This is a non-PDB format compatible entry.
Summary for 9MB4
Entry DOI10.2210/pdb9mb4/pdb
DescriptorMetallo-beta-lactamase type 2, ZINC ION, 3,3-bis(oxidanyl)-9-[(4-thiophen-2-yl-1,2,3-triazol-1-yl)methyl]-2,5-dioxa-3-boranuidabicyclo[4.4.0]deca-1(6),7,9-triene-10-carboxylic acid, ... (4 entities in total)
Functional Keywordsbeta lactamase, metallo beta lactamase ndm-1, carbapenemase, hydrolase
Biological sourceKlebsiella pneumoniae
Total number of polymer chains4
Total formula weight104318.97
Authors
Li, G.-B.,Yang, Z.-B.,Wei, S.-Q. (deposition date: 2025-03-15, release date: 2026-03-11)
Primary citationYang, Z.B.,Wei, S.Q.,Wang, Y.G.,Dong, X.M.,Xu, H.X.,Li, X.L.,Peng, J.,Yin, R.C.,Li, G.B.
Structural Optimization of Bicyclic Oxo-Boronates as Dual Metallo- and Serine-beta-Lactamase Inhibitors.
J.Med.Chem., 68:21807-21828, 2025
Cited by
PubMed Abstract: Gram-negative bacterial resistance to β-lactam antibiotics is a growing clinical problem, largely driven by the production of metallo-β-lactamases (MBLs) and serine-β-lactamases (SBLs). Developing dual inhibitors targeting both MBLs and SBLs has emerged as a focus in the fight against β-lactam resistance. We previously identified the bicyclic oxo-boronate as a dual MBL/SBL inhibitor through molecular generation based on the binding mode of carbapenem tetrahedral intermediates. Herein, we report the structural optimization of , yielding new bicyclic oxo-boronates with potent dual MBL/SBL inhibition, some of which could potentiate Meropenem efficacy against carbapenem-resistant Gram-negative superbugs. X-ray crystallography revealed a common binding mode of bicyclic oxo-boronates with VIM-2/NDM-1 MBL and OXA-48 SBL, mimicking the binding of carbapenem intermediates. exhibited pharmacokinetic characteristics similar to Meropenem and manifested efficacy when combined with Meropenem in a murine sepsis model. This work provides the basis for developing oxo-boronate-based inhibitors targeting MBLs/SBLs and other relevant targets.
PubMed: 41082617
DOI: 10.1021/acs.jmedchem.5c02230
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.441 Å)
Structure validation

250359

PDB entries from 2026-03-11

PDB statisticsPDBj update infoContact PDBjnumon